This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
18 Oct 2011

NIH Funds UCSF for Antimalarial Drugs Development

The National Institutes of Health funds the University of California San Francisco to discover and optimise oxaboroles as antimalarial drugs.

The National Institutes of Health (NIH) has granted $718,136 in funding to the University of California San Francisco (UCSF) to discover and optimise oxaboroles as antimalarial drugs.

 

UCSF has been in collaboration with Anacor Pharmaceuticals to develop new antimalarial agents.

 

Anacor also works with Medicines for Malaria Venture (MMV) to develop AN3661, a boron-based antimalarial compound currently in preclinical trials.

 

Anacor and MMV plan to conduct Phase 1 and Phase 2 proof of concept studies for AN3661, where GSK will have the option to license the programme.

Related News